sparse_primary_supporting_bucket
Central evidence is high but primary supporting bucket is empty. Classification tiers may still be too coarse.
fulltoplow inflation risk
Faecalibacterium prausnitzii
ulcerative colitis
Faecalibacterium prausnitzii appears to be a strong and relatively human-grounded signal in ulcerative colitis.
Faecalibacterium prausnitzii shows a strong literature footprint in ulcerative colitis, with substantial central evidence and broader supporting literature.
faecalibacterium_prausnitzii
Credibility score
100
Human translation
5/5
Reproducibility
5/5
Novelty
1/5
Actionability
5/5
Credibility 100Human translation 5/5Reproducibility 5/5Novelty 1/5Actionability 5/5
Why this scores the way it does
- strong central evidence base
- dense review literature
- substantial preclinical support
Main caveats
- directionality and confounding still require curated review
Internal review flags
1 flagsPrimary central evidence
41 papersLow counts of Faecalibacterium prausnitzii in colitis microbiota.
2009Inflammatory bowel diseases
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Microbiota of de-novo pediatric IBD: increased Faecalibacterium prausnitzii and reduced bacterial diversity in Crohn's but not in ulcerative colitis.
2012The American journal of gastroenterology
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Colonisation by Faecalibacterium prausnitzii and maintenance of clinical remission in patients with ulcerative colitis.
2013Alimentary pharmacology & therapeutics
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis.
2014Gut
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Mucosa-associated Faecalibacterium prausnitzii and Escherichia coli co-abundance can distinguish Irritable Bowel Syndrome and Inflammatory Bowel Disease phenotypes.
2014International journal of medical microbiology : IJMM
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Mucosa-associated Faecalibacterium prausnitzii phylotype richness is reduced in patients with inflammatory bowel disease.
2015Applied and environmental microbiology
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Changes in the Abundance of Faecalibacterium prausnitzii Phylogroups I and II in the Intestinal Mucosa of Inflammatory Bowel Disease and Patients with Colorectal Cancer.
2016Inflammatory bowel diseases
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Quantitative Analysis of Intestinal Flora of Uygur and Han Ethnic Chinese Patients with Ulcerative Colitis.
2016Gastroenterology research and practice
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Similar Depletion of Protective Faecalibacterium prausnitzii in Psoriasis and Inflammatory Bowel Disease, but not in Hidradenitis Suppurativa.
2016Journal of Crohn's & colitis
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Fecal microbiota in pouchitis and ulcerative colitis.
2016World journal of gastroenterology
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Longitudinal microbiome analysis of single donor fecal microbiota transplantation in patients with recurrent Clostridium difficile infection and/or ulcerative colitis.
2018PloS one
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Alterations in the Abundance and Co-occurrence of Akkermansia muciniphila and Faecalibacterium prausnitzii in the Colonic Mucosa of Inflammatory Bowel Disease Subjects.
2018Frontiers in cellular and infection microbiology
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Longitudinal Analyses of Gut-Associated Bacterial Microbiota in Ulcerative Colitis Patients.
2018Archives of Iranian medicine
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Mucosal 5-aminosalicylic acid concentration, drug formulation and mucosal microbiome in patients with quiescent ulcerative colitis.
2019Alimentary pharmacology & therapeutics
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Effects of Low FODMAP Diet on Symptoms, Fecal Microbiome, and Markers of Inflammation in Patients With Quiescent Inflammatory Bowel Disease in a Randomized Trial.
2020Gastroenterology
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Temporal Gut Microbial Changes Predict Recurrent Clostridiodes Difficile Infection in Patients With and Without Ulcerative Colitis.
2020Inflammatory bowel diseases
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
A randomized controlled trial investigating the effect of a diet low in fermentable oligosaccharides, disaccharides, monosaccharides, and polyols on the intestinal microbiome and inflammation in patients with ulcerative colitis: study protocol for a randomized controlled trial.
2020Trials
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Fecal microbiota transplantation ameliorates active ulcerative colitis.
2020Experimental and therapeutic medicine
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Low-Fat, High-Fiber Diet Reduces Markers of Inflammation and Dysbiosis and Improves Quality of Life in Patients With Ulcerative Colitis.
2021Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Gut dysbiosis and clinical phases of pancolitis in patients with ulcerative colitis.
2021MicrobiologyOpen
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Intestinal flora differences between patients with ulcerative colitis of different ethnic groups in China.
2021Medicine
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Long-Term Efficacy of Low-Intensity Single Donor Fecal Microbiota Transplantation in Ulcerative Colitis and Outcome-Specific Gut Bacteria.
2021Frontiers in microbiology
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Gut Microbiota Associated with Clinical Relapse in Patients with Quiescent Ulcerative Colitis.
2022Microorganisms
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Ulcerative Colitis in Response to Fecal Microbiota Transplantation via Modulation of Gut Microbiota and Th17/Treg Cell Balance.
2022Cells
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Location-specific signatures of Crohn's disease at a multi-omics scale.
2022Microbiome
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Gastrointestinal health: changes of intestinal mucosa and microbiota in patients with ulcerative colitis and irritable bowel syndrome from PM2.5-polluted regions of Ukraine.
2023Environmental science and pollution research international
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Impact of gut Microbiome alteration in Ulcerative Colitis patients on disease severity and outcome.
2023Clinical and experimental medicine
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Insight into gut dysbiosis of patients with inflammatory bowel disease and ischemic colitis.
2023Frontiers in microbiology
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Dynamics of the Gut Mycobiome in Patients With Ulcerative Colitis.
2024Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
The Role of Akkermansia muciniphila and Faecalibacterium prausnitzii in the Pathogenesis of Ulcerative Colitis and Crohn's Disease.
2024Clinical laboratory
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Clinical features and fecal microbiota characteristics of patients with both ulcerative colitis and axial spondyloarthritis.
2024BMC gastroenterology
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Cohabiting with ulcerative colitis patients decreases differences of gut microbiome between healthy individuals and the patients.
2024Annals of medicine
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Gut Microbial Species and Endotypes Associate with Remission in Ulcerative Colitis Patients Treated with Anti-TNF or Anti-integrin Therapy.
2024Journal of Crohn's & colitis
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Faecalibacterium prausnitzii A2-165 metabolizes host- and media-derived chemicals and induces transcriptional changes in colonic epithelium in GuMI human gut microphysiological system.
2024Microbiome research reports
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Changes in amino acid concentrations and the gut microbiota composition are implicated in the mucosal healing of ulcerative colitis and can be used as noninvasive diagnostic biomarkers.
2024Clinical proteomics
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Gut microbiota and blood biomarkers in IBD-Related arthritis: insights from mendelian randomization.
2025Scientific reports
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Improvement of the inflammation-damaged intestinal barrier and modulation of the gut microbiota in ulcerative colitis after FMT in the SHIME® model.
2025BMC complementary medicine and therapies
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Gut microbiome signatures predict 5-ASA efficacy in ulcerative colitis.
2025iScience
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Exploration of fecal microbiota in newly diagnosed patients with inflammatory bowel disease using shotgun metagenomics.
2025Frontiers in cellular and infection microbiology
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Predictive Microbial Markers Distinguish Responders and Non-Responders to Adalimumab: A Step Toward Precision Medicine in Ulcerative Colitis.
2025Microorganisms
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Gut microbiota profiling in Lebanese ulcerative colitis patients and healthy controls from a pilot study.
2025Scientific reports
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Preclinical supporting evidence
11 papers[Effects of Faecalibacterium prausnitzii supernatant on Th17 cell and IL-17A in dextran sulfate sodium-induced ulcerative colitis mice].
2015Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Faecalibacterium prausnitzii supernatant ameliorates dextran sulfate sodium induced colitis by regulating Th17 cell differentiation.
2016World journal of gastroenterology
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Gut microbiota regulation and anti-inflammatory effect of β-carotene in dextran sulfate sodium-stimulated ulcerative colitis in rats.
2021Journal of food science
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Fusobacterium nucleatum aggravates ulcerative colitis through promoting gut microbiota dysbiosis and dysmetabolism.
2023Journal of periodontology
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Lactobacillus plantarum ZJ316 alleviates ulcerative colitis by inhibiting inflammation and regulating short-chain fatty acid levels and the gut microbiota in a mouse model.
2023Food & function
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Faecalibacterium prausnitzii, Bacteroides faecis and Roseburia intestinalis attenuate clinical symptoms of experimental colitis by regulating Treg/Th17 cell balance and intestinal barrier integrity.
2023Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Systematic druggable genome-wide Mendelian randomization to identify therapeutic targets and dominant flora for ulcerative colitis.
2025Pharmacological research
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Therapeutic effect of Faecalibacterium longum CM04-06 on DSS-induced ulcerative colitis in mice.
2025Journal of applied microbiology
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Reshaping the gut microbiota to ameliorate DSS-induced colitis using a novel synbiotic consisting of jujube powder and Faecalibacterium prausnitzii.
2025Food & function
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Faecalibacterium prausnitzii Ameliorates DSS-Induced Colitis via Modulating Bile Acid Metabolism and Regulating FXR Signaling.
2025Digestive diseases and sciences
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Faecalibacterium prausnitzii enhances intestinal IgA response by host-microbe derived inecalcitol in colitis.
2025BMC medicine
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Review supporting evidence
13 papersEnteric microbiota leads to new therapeutic strategies for ulcerative colitis.
2014World journal of gastroenterology
Relevant review or meta-analysis for the signal-disease area.
Faecalibacterium prausnitzii: from microbiology to diagnostics and prognostics.
2017The ISME journal
Relevant review or meta-analysis for the signal-disease area.
Influence of Microbiota on Intestinal Immune System in Ulcerative Colitis and Its Intervention.
2017Frontiers in immunology
Relevant review or meta-analysis for the signal-disease area.
Differences in Gut Microbiota in Patients With vs Without Inflammatory Bowel Diseases: A Systematic Review.
2020Gastroenterology
Relevant review or meta-analysis for the signal-disease area.
Systematic review and meta-analysis of the role of Faecalibacterium prausnitzii alteration in inflammatory bowel disease.
2021Journal of gastroenterology and hepatology
Relevant review or meta-analysis for the signal-disease area.
Research trends in ulcerative colitis: A bibliometric and visualized study from 2011 to 2021.
2022Frontiers in pharmacology
Relevant review or meta-analysis for the signal-disease area.
Gut microbiota and metabolites as predictors of biologics response in inflammatory bowel disease: A comprehensive systematic review.
2024Microbiological research
Relevant review or meta-analysis for the signal-disease area.
Inflammatory Bowel Disease and Colorectal Cancer: An Eternal Fire in a Beautiful Garden.
2024South Asian journal of cancer
Relevant review or meta-analysis for the signal-disease area.
Gut Microbiota Serves as a Crucial Independent Biomarker in Inflammatory Bowel Disease (IBD).
2025International journal of molecular sciences
Relevant review or meta-analysis for the signal-disease area.
Impact of Psychopathology and Gut Microbiota on Disease Progression in Ulcerative Colitis: A Five-Year Follow-Up Study.
2025Microorganisms
Relevant review or meta-analysis for the signal-disease area.
The gut immune axis in ulcerative colitis: insights from microbiome research.
2025Molecular biology reports
Relevant review or meta-analysis for the signal-disease area.
Diet and Gut Microbiota in Inflammatory Bowel Disease: A Clinical and Nutritional Perspective.
2026Pharmaceuticals (Basel, Switzerland)
Relevant review or meta-analysis for the signal-disease area.
The Role of Microbiota and Fecal Transplantation in Inflammatory Bowel Disease.
2026Pathogens (Basel, Switzerland)
Relevant review or meta-analysis for the signal-disease area.